



## **MaaT Pharma to Hold Annual General Meeting on June 16, 2026**

**Lyon, France, May 11, 2026 – 6:00pm CET – [MaaT Pharma](#) (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem Therapies™ (MET) dedicated to enhancing survival for patients with cancer through immune modulation, informs its shareholders that the Annual General Meeting (ordinary and extraordinary) will be held on June 16, 2026, at 9:30am CET at the Company’s headquarter in France located at 70 avenue Tony Garnier, 69007 Lyon and will also be broadcasted live.**

The notice of meeting, serving as convening notice is published in the *Bulletin des annonces légales obligatoires* on Monday, 11 May 2026 ([www.journal-officiel.gouv.fr/pages/balo](http://www.journal-officiel.gouv.fr/pages/balo)), in bulletin no. 56 (reference 2601636). It contains the detailed agenda, the draft resolutions and the main terms and conditions of participation and voting at this meeting.

The convening notice will be published in the *Journal des annonces légales “Le Tout Lyon”* on 27 May 2026. It will also be sent to registered shareholders and made available to institutions holding bearer shares.

The documents and information relating to this General Meeting have been and will be, in accordance with the applicable laws and regulations:

- posted on MaaT Pharma's website ([www.maatpharma.com/investors](http://www.maatpharma.com/investors)) under the section "Investors/General Meetings/2026";
- made available to shareholders at the Company's registered office at 70 avenue Tony Garnier, 69007 Lyon, France;
- and sent to shareholders by Uptevia - Service Assemblées Générales, 90 - 110 Esplanade du Général de Gaulle - 92931 Paris La Défense Cedex, on receipt of their request.

Further information on this General Meeting, and on how shareholders can vote, is available on MaaT Pharma’s website under the [Investors section](#) ("Participating in the General Meeting").

The General Meeting will be broadcast live via a dedicated platform and can be accessed through the link [here](#). A recording of the General Meeting will be made available on the Company’s website within the timeframe required by applicable regulations.

### **Financial Calendar\***

- May 26, 2026: Publication of Q1 2026 revenue and cash position
- June 16, 2026: Annual General Meeting
- September 15, 2026: Publication of H1 2026 results
- November 16, 2026: Publication of Q3 2026 revenue and cash position

*(\*Indicative calendar that may be subject to change.)*

---

### **About MaaT Pharma**

MaaT Pharma is a leading, late-stage clinical company focused on developing innovative gut microbiome-driven therapies to modulate the immune system and enhance cancer patient survival. Supported by a talented team committed to making a difference for patients worldwide, the Company was founded in 2014 and is based in Lyon, France.

As a pioneer, MaaT Pharma is leading the way in bringing the first microbiome-driven immunomodulator in oncology. Using its proprietary pooling and co-cultivation technologies, MaaT Pharma develops high diversity, standardized drug candidates, aiming at extending life of cancer patients. MaaT Pharma has been listed on Euronext Paris (ticker: MAAT) since 2021.



### **Forward-looking Statements**

All statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the Company's control. These statements may include, without limitation, any statements preceded by, followed by, or including words such as "target," "believe," "expect," "aim", "intend," "may," "anticipate," "estimate," "plan," "project," "will," "can have," "likely," "should," "would," "could" and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company's control that could cause the Company's actual results or performance to be materially different from the expected results or performance expressed or implied by such forward-looking statements.

### **Contacts**

#### **MaaT Pharma – Investor Relations**

Eric Soyer  
Chief Financial Officer  
+33 4 28 29 14 00  
[invest@maat-pharma.com](mailto:invest@maat-pharma.com)

#### **MaaT Pharma – Media Relations**

Pauline Richaud  
Head of Communications  
+33 6 14 06 45 92  
[media@maat-pharma.com](mailto:media@maat-pharma.com)